case_images: PMC11366101_01
case_images: Immunostaining of biopsy specimens positive for CD68, CD163, LCA, lysozyme, and PD-L1 (VENTANA SP263, Roche).
case_images: 10.1177_23247096241274561-fig1.jpg
case_images: PMC11366101_01_10.1177_23247096241274561-fig1.jpg
case_images: fig1-23247096241274561
case_images: The Ki-67 proliferation index was 30% (Figure 1). Immunostaining revealed that more than 90% of tumor cells in the initial biopsy specimen exhibited significant PD-L1 overexpression (refer to the list of papers in Figure 1). Additionally, FISH analysis identified copy number amplification of JAK-2 in these tumor cells (Supplementary Figure 1).
case_images: A comprehensive 18F-FDG-PET scan of the entire body reveals a substantial decrease in lesion size following treatment with immune checkpoint inhibitors (A) Lesions observed at initial diagnosis; (B) Partial lesion remission post-induction protocol; (C) Disease progression after multiple conventional chemotherapy regimens; (D and E) Efficacy observed with ICI in combination with GDP chemotherapy; (F) Sustained complete remission exceeding 4 years at the latest follow-up.
case_images: 10.1177_23247096241274561-fig2.jpg
case_images: PMC11366101_01_10.1177_23247096241274561-fig2.jpg
case_images: fig2-23247096241274561
case_images: Positron emission tomography/computed tomography (PET/CT) indicated partial remission of the lesion (Figure 2B). Nevertheless, interim PET-CT revealed no improvement in the residual lesion and identified new hypermetabolic activity in the T4 thoracic spine, indicative of disease progression (Figure 2C). After four chemotherapy cycles, the patient's overall condition improved, B symptoms resolved, and PET-CT scans indicated an effective response (Figure 2D and E). PET-CT scans at the latest follow-up confirmed ongoing complete remission for over 4 years (Figure 2F).